Boston Partners
SCMP

Boston Partners’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Boston Partners’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-238,519
Closed -$2.94M – 785
2016
Q3 		$2.94M Hold
238,519
– – ﹤0.01% 594
2016
Q2 		$2.62M Buy
238,519
+63,965
+37% +$716K ﹤0.01% 595
2016
Q1 		$1.91M Buy
+174,554
New +$2.21M ﹤0.01% 627

Other funds holding SCMP

LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return

Boston Partners's SCMP Position: Q4 2016 in Review

Boston Partners sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2016, closing a stake of 238,519 shares — an estimated $2.94M sold.

Boston Partners first reported a position in SCMP in Q1 2016 and held it in 3 quarters. The position peaked at $2.94M in Q3 2016. 165 funds tracked by Wall St. Rank hold SCMP as of Q4 2016.

  • Boston Partners reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Boston Partners sold 238,519 Sucampo Pharmaceuticals, Inc. shares in Q4 2016, an estimated $2.94M.
  • Boston Partners first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2016 and held it in 3 quarters.
  • Boston Partners's Sucampo Pharmaceuticals, Inc. position peaked at $2.94M in Q3 2016.
  • 165 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2016.

Based on Boston Partners's 13F filing for Q4 2016, filed 6 Feb 2017.